FM/a® – The Fibromyalgia Test

Lessens the Burden of a Lengthy, Costly, and Painful Diagnostic Journey

Finally the source code that uncovers the medical disease called fibromyalgia is available via an objective, multiple biomarker-based diagnostic test that has documented the altered immunology of the fibromyalgia patient.

Two separate medical studies were conducted at the University of Illinois College of Medicine at Chicago which investigated the uniqueness of the fibromyalgia patient. Via the University of Illinois College of Medicine at Chicago, Department of Pathology, a CLIA certified laboratory, a rigorous analysis of fibromyalgia patients versus matched healthy control individuals revealed a distinct set of immunologic markers in those who have fibromyalgia. This test proves that there are no boundaries when it comes to age, gender or ethnicity in reference to the development of fibromyalgia.

Fibromyalgia can now be documented as a real world affliction and not the speculative, non-quantifiable collection of miscellaneous complaints composed primarily of a subjective syndrome of symptoms. Fibromyalgia ceases to be a “wastebasket diagnosis ®.”

FM/a ® reveals that this disorder, whether called fibromyalgia, fibrositis, the chronic fatigue syndrome or fibromyocitis, among other names is really an immune system dysregulation disease. Patients who test positive for FM/a ® will no longer be labeled neurotic, hypochondrical chronic complainers. Theirs is an actual illness with objectively measurable traits.

Many of the World’s Leading FM Experts

Have Affiliated Themselves With Epic’s Diagnostic Test for Fibromyalgia

EpicGenetics has worked hard to earn the trust and respect of a renowned group of eleven scientists and doctors from around the world who now serve as its scientific and medical advisory board for FM/a® – The FM Test — as well as for current and future research in Fibromyalgia and several other important areas.

Members of Epic’s advisory board hail from Harvard, Cornell, University of Illinois, UCLA, University of Vienna, Shanghai University, Leiden University, The Hospital for Special Surgery, as well as private practice.

As just one example of the Epic SAB’s expertise and credentials, the team includes Daniel J. Wallace, MD, associate director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, and clinical professor at the David Geffen School of Medicine at UCLA.

Dr. Wallace is the author of six medical textbooks including “All About Fibromyalgia”, “The Lupus Book”, “All About Osteoarthritis”, “The New Sjogren’s Syndrome Handbook”, and “Fibromyalgia & Other Central Pain Syndromes”, as well as 25 book chapters, and more than 300 medical publications.

For more information about our world-leading experts, you are invited to click here and follow the links to more information about each of the them.

Startling Statistics

5
years, experts say, is how long, until now, it has taken to be finally, correctly and objectively diagnosed with FM.

26,218
dollars are spent annually (incl. direct and indirect costs) on a patient suffering with "moderate" level FM.

6.4
percent of the general population suffers with fibromyalgia, according to a recent Mayo Clinic study.
From Dr. Dan Wallace

“The elegantly designed study by Dr. Gillis and his co-investigators represents a milestone on the path our group charted 25 years ago when we first hypothesized that cytokines play a role in fibromyalgia*. It is hoped that this and future work sponsored by EpicGenetics will lead to a greater understanding of how the immune system, fatigue, sleep disorders, chronic stress and pain interact in patients with fibromyalgia and related disorders.”

Daniel J. Wallace, MD, FACP, FACR, a clinical professor of medicine at the David Geffen School of Medicine at UCLA based at Cedars-Sinai Medical Center.

* D Wallace et al, Annals of Internal Medicine, 1988; 108: 909.

Privacy Statement & Health Information Privacy Practices ∙ Conditions of Use